Wratizolin ITCL in the treatment of herpes simplex and recurrent and zoster.
Herpes simplex and zoster are frequent skin diseases of viral origin and the mechanism of their development as well as their course are not yet fully known. Fully effective methods of treating these diseases are not known. The authors evaluated the results of the externally applied ITCL preparation in the form of a 2% cream. A group of 92 patients was treated, 64 with herpes simplex or recurrent, 16 with zoster, 9 with purulent skin lesions and 3 with verruca plana. Very good results, that is earlier regression of lesions with inhibition of further dissemination, were obtained in 83% of patients with herpes, in over half of the cases of zoster, and in nearly all cases with purulent skin lesions. In most cases the tolerance of the drug was good.
D000293:Adolescent; D000328:Adult; D000368:Aged; D000998:Antiviral Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D002648:Child; D005260:Female; D006561:Herpes Simplex / Q000188:drug therapy; D006562:Herpes Zoster / Q000188:drug therapy; D006801:Humans; D008297:Male; D008875:Middle Aged; D009824:Ointments; D011711:Pyoderma / Q000188:drug therapy; D012008:Recurrence; D012874:Skin Diseases, Infectious / Q000188:drug therapy*; D013844:Thiazoles / Q000494:pharmacology*; D014860:Warts / Q000188:drug therapy
D000998:Antiviral Agents; D009824:Ointments; D013844:Thiazoles; C027999:5-(benzoylamino)-N-(4-chlorophenyl)-3-methyl-4-isothiazolecarboxamide